David Granger, DPM
Podiatrist · York, PANPI 1144400458
Payments from drug & device makers
What this record shows
Paragon 28, Inc. accounts for 78.1% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2021 at $1,041 and has fallen 96.5% since, to $36 in 2025.
Across 23 payments — averaging $66.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Paragon 28, Inc.$1K
- Stryker$67
- Johnson & Johnson$67
- Ossio Inc$56
- Organogenesis Inc.$43
- Globus Medical$28
- plus $73 from 4 others
Across 5 payments — averaging $5017.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Paragon 28, Inc.$25K
What the payments were for
- Travel & lodging$76050%
- Food & beverage$76050%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Paragon 28, Inc. | 10 | $1,187 |
| Stryker | 3 | $67 |
| Johnson & Johnson | 2 | $67 |
| Ossio Inc | 1 | $56 |
| Organogenesis Inc. | 1 | $43 |
| Globus Medical | 2 | $28 |
| Solventum Corporation | 1 | $21 |
| Urgo Medical North America, LLC | 1 | $20 |
| Smith+Nephew | 1 | $16 |
| Bioventus LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Product Portfolio$511
- APEX 3D$487
How this compares
$1,520 in reported general payments places this provider in the 65th percentile of 445 podiatrist providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Terbinafine Hcl | 58 | $276 |
| Oxycodone Hcl | 73 | $185 |
| Gabapentin | 25 | $171 |
| Prednisone | 47 | $153 |
| Dexamethasone Sodium Phosphate | 17 | $138 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 13 | $128 |
| Methylprednisolone | 14 | $76 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 13 | $55 |
| Meloxicam | 28 | $49 |
| Tramadol Hcl | 17 | $25 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in York
- John LapelusaYork$54K
- Samuel ClellenYork$29K
- Rachel WarnerYork$26K
- Rahim LakhaniYork$21K
- Michael FalciYork$9K
- Sonam RuitYork$7K
- Mark HofbauerBelle Vernon$1.1M
- Daniel PerezPhiladelphia$434K
- Christopher BarrettChester$229K
- Alan CatanzaritiPittsburgh$80K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.